OrbiMed Advisors Portfolio
13F Holdings & Position Changes — Last filed Aug 14, 2026
13F Holdings & Position Changes — Last filed Aug 14, 2026
One of the world's largest healthcare-dedicated investment firms, managing assets across public equity, private equity, royalties, and credit. OrbiMed's team of 100+ professionals includes physicians and PhDs covering all healthcare sub-sectors, with particular depth in biotech and pharma.
OrbiMed Advisors is a $19B biotech-focused hedge fund managed by Jonathan Silverstein (Executive Partner). As of their latest 13F filing (Q2 2026), the fund holds 111 positions worth $5.1B. This quarter they initiated 15 new positions and exited 115. Their largest holding is EWTX ($630.5M).
OrbiMed initiated 15 new positions and increased 44 this quarter. Portfolio grew +19.9% to $5.1B. 1000 upcoming catalysts across holdings.
Portfolio Value (13F)
$5.1B
Holdings
111
Top 10 Concentration
44.4%
QoQ Change
+19.9%
Turnover
3.1%
Portfolio Value Trend
Be first to know when OrbiMed Advisors files next quarter
Get an email the moment new buys, exits, and conviction changes hit. Free 14-day trial.
| # | Ticker | Company | Change | Value | % of Portfolio | SI % Float ? | Trend |
|---|---|---|---|---|---|---|---|
| 1 | EWTX | Edgewise Therapeutics, Inc. | $630.5M | 12.32% | 12.6% | ||
| 2 | ELVN | Enliven Therapeutics, Inc. | Decreased | $343.9M | 6.72% | 16.2% | |
| 3 | LLY | Eli Lilly & Co | Increased | $309.3M | 6.04% | 0.7% | |
| 4 | MBX | MBX Biosciences, Inc. | Decreased↓3Q | $189.3M | 3.70% | 14.3% | |
| 5 | SVA | Sinovac Biotech Ltd. | $184.5M | 3.60% | — | ||
| 6 | AZN | Astrazeneca Plc | Increased↑2Q | $171.1M | 3.34% | 0.1% | |
| 7 | GPCR | Structure Therapeutics Inc. | Increased↑3Q | $118.6M | 2.32% | 11.7% | |
| 8 | SION | Sionna Therapeutics, Inc. | Decreased↓3Q | $112.4M | 2.20% | 15.2% | |
| 9 | CRVS | Corvus Pharmaceuticals Inc. | $107.0M | 2.09% | 25.9% | ||
| 10 | AVBP | ArriVent BioPharma, Inc. | $105.2M | 2.06% | 17.7% |
Share changes reflect active decisions. Value changes include price moves.
Track this fund’s next move
13F changes, conviction shifts, and catalyst alerts across all 20 specialist biotech funds — free Monday brief.
See all 111 holdings (you're viewing the top 10), plus 5 quarters of position history.
No charge for 14 days · Cancel anytime
OrbiMed Advisors held 111 biotech stocks in their 13F portfolio this quarter. Their top positions include EWTX, ELVN, LLY, MBX, SVA. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
OrbiMed Advisors's tracked biotech portfolio is worth $5.1B across 111 positions, with total assets under management of approximately $19B. Portfolio values are based on 13F filings with the SEC.
OrbiMed Advisors initiated 15 new positions this quarter, including ODTX, AURA, MNPR, TSHA, SPRB and 10 more. They also increased 44 existing positions.
OrbiMed Advisors fully exited 115 positions this quarter, including AGIO, AVTX, AKRO, MNMD, TIL and 110 more. They also trimmed 26 existing positions.
One of the world's largest healthcare-dedicated investment firms, managing assets across public equity, private equity, royalties, and credit. OrbiMed's team of 100+ professionals includes physicians and PhDs covering all healthcare sub-sectors, with particular depth in biotech and pharma.
Track specialist biotech funds, insider signals, and AI analysis
Start 14-Day Free Trial